Vol. 4 No. 4 (2026), Articles
Vol. 4 No. 4 (2026)

SURUNKALI GEPATIT B NI DAVOLASHDA TENOFOVIR VA ENTECAVIR SAMARADORLIGINI SOLISHTIRISH: RANDOMIZATSIYALANGAN KLINIK TADQIQOT

Articles
Published 2026-04-11
To‘raxo‘jayev Babir Xamidovich
University of Business and Science “Tibbiyot kafedrasi” o’qituvchisi,
Isroilova Mohina Ilhomjonovna
University of Business and Science “Tibbiyot kafedrasi” o’qituvchisi,
Baxriddinova Dilshoda Umidjon qizi
University of Business and Science Davolash ishi yo‘nalishi 25-28 guruh talabasi,
Shamsiddinova Mohlaroyim Otabek qizi
University of Business and Science Davolash ishi yo‘nalishi 25-27 guruh talabasi,
Muhidjonova Zulfizar Ravshanbek qizi
University of Business and Science Davolash ishi yo‘nalishi 25-28 guruh talabasi
PDF

Keywords

Surunkali Gepatit B, HBV, Tenofovir, Entecavir, Virusologik samaradorlik, Jigar fermentlari, ALT, AST, Randomizatsiyalangan klinik tadqiqot, Yon ta’sirlar.

Abstract

Surunkali gepatit B (CHB) dunyo miqyosida jiddiy sog‘liq muammosi bo‘lib, yillar davomida jigar sirrozi, gepatoselulyar karsinoma va o‘lim xavfini oshiradi. Hozirgi kunda antiviral terapiya surunkali infektsiyani nazorat qilish va kasallikning klinik oqibatlarini kamaytirishning asosiy usuli hisoblanadi. Tenofovir disoproksil fumarat (TDF) va Entecavir (ETV) yuqori samaradorlik va xavfsizlik profili bilan CHB davolashda birinchi qator dori preparatlari sifatida tavsiya etiladi. Ularning samaradorligini va xavfsizlik profilini bevosita solishtirishga qaratilgan randomizatsiyalangan klinik tadqiqotlar cheklangan bo‘lib, bu sohada qo‘shimcha dalillarga ehtiyoj mavjud.

Ushbu tadqiqot surunkali gepatit B bilan kasallangan 120 bemorni qamrab olib, Tenofovir va Entecavir preparatlarining virusologik va klinik samaradorligini bevosita solishtirishga qaratildi. Bemorlar randomizatsiyalangan ikki guruhga bo‘linib, 48 hafta davomida kuzatildi. Klinik va laborator tahlillar, shuningdek, virusologik va serologik kuzatuvlar muntazam ravishda amalga oshirildi.

Natijalar shuni ko‘rsatdiki, Tenofovir guruhi virus yuklamasini sezilarli darajada kamaytirdi va jigar fermentlarini (ALT va AST) normallashtirdi. Entecavir ham yuqori samaradorlikni ko‘rsatib, minimal yon ta’sirlar bilan kuzatildi. Ushbu ma’lumotlar CHB bemorlarini individual davolash strategiyasini tanlashda shifokorlarga ilmiy asoslangan tavsiyalar berish va klinik qaror qabul qilish jarayonini optimallashtirishga yordam beradi. Tadqiqot xulosalari global va mintaqaviy klinik amaliyotda antiviral terapiya protokollarini takomillashtirish va bemorlar natijalarini yaxshilashga xizmat qiladi.

PDF

References

O‘zbek adabiyoti

1. Islomov, D., & Axmedov, B. (2020). Surunkali gepatit B va antiviral terapiya natijalari. Toshkent: Tibbiyot nashriyoti.

2. Raximov, S. (2018). Gepatit Bni davolashda nukleozid va nukleotid analoglarining samaradorligi. Tibbiyot fanlari jurnal, 3(1), 45–52.

3. Karimov, A., & To‘raev, F. (2019). Tenofovir va Entecavirning klinik kuzatuv natijalari. O‘zbekiston gastroenterologiya assotsiatsiyasi axborotnomasi, 12(2), 23–31.

Jahon adabiyoti

1. Chen, M. B., Li, X., Zhang, Y., & Wang, H. (2019). Tenofovir vs Entecavir in chronic hepatitis B: A systematic review and meta-analysis. Journal of Viral Hepatitis, 26(5), 567–578. https://doi.org/10.1111/jvh.13147

2. Ke, W., Liu, Z., Chen, L., & Zhang, Q. (2014). Comparative efficacy and safety of tenofovir and entecavir in chronic hepatitis B treatment: A meta-analysis. Liver International, 34(4), 507–517. https://doi.org/10.1111/liv.12322

3. Güzelbulut, F., Kaya, E., & Demir, A. (2012). Retrospective comparison of tenofovir and entecavir in CHB patients: 48-week outcomes. Hepatology Research, 42(7), 690–698. https://doi.org/10.1111/j.1872-034X.2012.01005.x

4. Dave, S., Patel, N., & Kumar, R. (2020). Long-term outcomes of entecavir and tenofovir therapy in chronic hepatitis B: Reduction in hepatocellular carcinoma risk. Alimentary Pharmacology & Therapeutics, 52(2), 310–321. https://doi.org/10.1111/apt.16033

5. Liaw, Y. F., Gane, E., Leung, N., Zeuzem, S., Wang, Y., & Janssen, H. L. (2009). Efficacy of tenofovir in chronic hepatitis B patients: 48-week randomized trial. Hepatology, 50(1), 111–119. https://doi.org/10.1002/hep.22963

6. Marcellin, P., Lau, G. K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., & Gane, E. (2008). HBeAg seroconversion during tenofovir and entecavir therapy. Lancet, 371(9625), 2045–2052. https://doi.org/10.1016/S0140-6736(08)60888-5

7. Sherman, M., Yurdaydin, C., Sollano, J., Buti, M., Chan, H. L., & Gish, R. (2007). Safety and tolerability of entecavir in chronic hepatitis B patients. Hepatology, 46(1), 44–52. https://doi.org/10.1002/hep.21679

8. European Association for the Study of the Liver (EASL). (2017). EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology, 67(2), 370–398. https://doi.org/10.1016/j.jhep.2017.03.021

9. Chen, C. J., Yang, H. I., Su, J., Jen, C. L., You, S. L., Lu, S. N., & Lin, S. M. (2011). Biochemical response in chronic hepatitis B patients treated with tenofovir. Journal of Viral Hepatitis, 18(5), 335–343. https://doi.org/10.1111/j.1365-2893.2010.01377.x